250 related articles for article (PubMed ID: 21145600)
1. Reactivation of p53: from peptides to small molecules.
Brown CJ; Cheok CF; Verma CS; Lane DP
Trends Pharmacol Sci; 2011 Jan; 32(1):53-62. PubMed ID: 21145600
[TBL] [Abstract][Full Text] [Related]
2. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
Toledo F; Wahl GM
Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
[TBL] [Abstract][Full Text] [Related]
3. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
4. Peptide activators of the p53 tumor suppressor.
Zhan C; Lu W
Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
[TBL] [Abstract][Full Text] [Related]
5. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
[TBL] [Abstract][Full Text] [Related]
6. Stapled peptides with improved potency and specificity that activate p53.
Brown CJ; Quah ST; Jong J; Goh AM; Chiam PC; Khoo KH; Choong ML; Lee MA; Yurlova L; Zolghadr K; Joseph TL; Verma CS; Lane DP
ACS Chem Biol; 2013 Mar; 8(3):506-12. PubMed ID: 23214419
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
[TBL] [Abstract][Full Text] [Related]
8. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4.
Marine JC; Francoz S; Maetens M; Wahl G; Toledo F; Lozano G
Cell Death Differ; 2006 Jun; 13(6):927-34. PubMed ID: 16543935
[No Abstract] [Full Text] [Related]
9. Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.
Teveroni E; Lucà R; Pellegrino M; Ciolli G; Pontecorvi A; Moretti F
Expert Opin Ther Pat; 2016 Dec; 26(12):1417-1429. PubMed ID: 27603098
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.
Zhang R; Mayhood T; Lipari P; Wang Y; Durkin J; Syto R; Gesell J; McNemar C; Windsor W
Anal Biochem; 2004 Aug; 331(1):138-46. PubMed ID: 15246006
[TBL] [Abstract][Full Text] [Related]
11. Turning the key on p53.
Lane DP; Fischer PM
Nature; 2004 Feb; 427(6977):789-90. PubMed ID: 14985740
[No Abstract] [Full Text] [Related]
12. p53 as a target for the treatment of cancer.
Duffy MJ; Synnott NC; McGowan PM; Crown J; O'Connor D; Gallagher WM
Cancer Treat Rev; 2014 Dec; 40(10):1153-60. PubMed ID: 25455730
[TBL] [Abstract][Full Text] [Related]
13. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
[TBL] [Abstract][Full Text] [Related]
15. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
16. The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.
Zheleva DI; Lane DP; Fischer PM
Mini Rev Med Chem; 2003 May; 3(3):257-70. PubMed ID: 12698949
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q; Lozano G
Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
[TBL] [Abstract][Full Text] [Related]
18. Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy.
Lu M; Miller P; Lu X
FEBS Lett; 2014 Aug; 588(16):2616-21. PubMed ID: 24844434
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Shangary S; Wang S
Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
[TBL] [Abstract][Full Text] [Related]
20. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
